Neuralstem, Inc.

Neuralstem (NASDAQ:CUR) is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need.  Our lead asset, NSI-189, is a new chemical entity in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, neuropathy associated with Type 1 and Type 2 diabetes, and stroke.  Our lead stem cell therapy candidate, NSI-566, is a spinal cord-derived neural stem cell line being tested in Amyotrophic Lateral Sclerosis (ALS), chronic spinal cord injury (cSCI), and ischemic stroke. These product candidates are based on the company’s proprietary neural stem cell technology.


Bank Name Neuralstem, Inc.
Stock Exchange NASDAQ
Symbol CUR
Sector Healthcare
Industry Biotechnology: Biological Products
Country United States
World Region Amarica
Chairman Mr. Richard J. Daly
CEO Mr. Richard J. Daly
Employees 6
Registered Year 1996